Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2020

Kaur Harsimar, Salles Daniela C, Murali Sanjana, Hicks Jessica L, Nguyen Minh, Pritchard Colin C, De Marzo Angelo M, Lanchbury Jerry S, Trock Bruce J, Isaacs William B, Timms Kirsten M, Antonarakis Emmanuel S, Lotan Tamara L

Abstract excerpt

PURPOSE: The ATM (ataxia telangiectasia mutated) gene is mutated in a subset of prostate cancers, and ATM mutation may confer specific therapeutic vulnerabilities, although ATM-deficient prostate cancers have not been well-characterized. EXPERIMENTAL DESIGN: We genetically validated a clinical grade IHC assay to detect ATM protein loss and examined the frequency of ATM loss among tumors with pathogenic germline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins
Share to Datasets as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Grading

Share to Progression-Free Survival

Share to Prostate

Share to Prostatectomy

Share to Prostatic Neoplasms

Share to Tissue Array Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 32694154
DOI: 10.1158/1078-0432.CCR-20-0764
PMCID: PMC7501149

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and Clinicopathologic Characterization of ATM-deficient Prostate Cancer.PMID 32694154Read ↗

ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate CancerSemantic proximity Read ↗

Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes.Semantic proximity Read ↗

Molecular landscape of prostate cancer: Implications for current clinical trialsSemantic proximity Read ↗

Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage.Semantic proximity Read ↗

BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression.Semantic proximity Read ↗

Homologous recombination deficiency and genomic alterations in advanced prostate cancer: insights for precision therapy.Semantic proximity Read ↗

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B TrialSemantic proximity Read ↗

Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study.Semantic proximity Read ↗

Molecular Characterization and Clinical Outcomes of Primary Gleason Pattern 5 Prostate Cancer After Radical ProstatectomySemantic proximity Read ↗

Genomic aberration based molecular signatures efficiently characterize homologous recombination deficiency in prostate cancerSemantic proximity Read ↗

Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at DeathSemantic proximity Read ↗

Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.